Lawrence Alleva - Mersana Therapeutics Independent Director
| MRSN Stock | USD 3.17 0.01 0.32% |
Director
Mr. Lawrence M. Alleva is an Independent Director of the company. He is a Certified Public Accountant and is a former partner with PwC, where he worked for years until his retirement in June 2010, including 28 years service as a partner. He has worked with numerous pharmaceutical and biotechnology companies as clients and served PwC in a variety of office, regional and national practice leadership roles, most recently as the U.S. Ethics and Compliance Leader for the firms Assurance Practice from 2006 until 2010. Mr. Alleva currently serves as a director and chair of the audit committee for multiple public companies Tesaro Inc., Bright Horizons Family Solutions Inc. and Adaptimmune Therapeutics plc. He previously served as a Trustee of Ithaca College for over 20 years since 2017.
| Age | 67 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 840 Memorial Drive, Cambridge, MA, United States, 02139 |
| Phone | 617 498 0020 |
| Web | https://www.mersana.com |
Mersana Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3813) % which means that it has lost $0.3813 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6624) %, meaning that it created substantial loss on money invested by shareholders. Mersana Therapeutics' management efficiency ratios could be used to measure how well Mersana Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of May 2024, Return On Tangible Assets is likely to drop to -0.8. In addition to that, Return On Capital Employed is likely to drop to -1.11. At this time, Mersana Therapeutics' Fixed Asset Turnover is very stable compared to the past year. As of the 1st of May 2024, Asset Turnover is likely to grow to 0.23, while Total Assets are likely to drop about 180.4 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Robert Hoffman | Kura Oncology | 52 | |
| Ivor Royston | Syndax Pharmaceuticals | 72 | |
| William Waddill | Protagonist Therapeutics | 60 | |
| Otello Stampacchia | Replimune Group | 48 | |
| Patrick Machado | Arcus Biosciences | 55 | |
| Richard Shea | Syndax Pharmaceuticals | 63 | |
| Isaac Blech | X4 Pharmaceuticals | N/A | |
| Antoni Ribas | Arcus Biosciences | 53 | |
| Lucio Tozzi | Protagonist Therapeutics | 51 | |
| Bruce Leith | Terns Pharmaceuticals | N/A | |
| Andrew Perlman | Arcus Biosciences | 72 | |
| Pascal Brandys | Cerevel Therapeutics Holdings | 55 | |
| David Lacey | Arcus Biosciences | 67 | |
| Kathryn Falberg | Arcus Biosciences | 60 | |
| Murray Stewart | X4 Pharmaceuticals | 57 | |
| Joseph Slattery | Replimune Group | 53 | |
| Keith Katkin | Syndax Pharmaceuticals | N/A | |
| William Meury | Syndax Pharmaceuticals | 49 | |
| Hyam Levitsky | Replimune Group | 59 | |
| Sander Slootweg | Replimune Group | 48 | |
| Armen Shanafelt | Protagonist Therapeutics | 57 | |
Management Performance
| Return On Equity | -2.66 | ||||
| Return On Asset | -0.38 |
Mersana Therapeutics Leadership Team
Elected by the shareholders, the Mersana Therapeutics' board of directors comprises two types of representatives: Mersana Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mersana. The board's role is to monitor Mersana Therapeutics' management team and ensure that shareholders' interests are well served. Mersana Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mersana Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Damelin, Oncology, Biology | ||
| Ashish Mandelia, Vice President Controller | ||
| Mohan Bala, Senior Officer | ||
| Tushar Misra, Senior Officer | ||
| Eva Jack, Chief Business Officer | ||
| MD Huber, CEO President | ||
| Willard Dere, Independent Director | ||
| Michael Kaufman, Senior Vice President - Chemistry, Manufacturing and Controls | ||
| Andrew Hack, Independent Director | ||
| Wayne Foster, Vice President - Finance | ||
| Dirk Huebner, Chief Medical Officer | ||
| Anna MBA, CEO Pres | ||
| Brian DeSchuytner, Senior Vice President - Finance and Product Strategy | ||
| Chuck Miller, Senior Affairs | ||
| Carla Poulson, Chief Officer | ||
| Martin MD, CEO President | ||
| Jason Fredette, Senior Communications | ||
| David Spellman, CFO | ||
| Lawrence Alleva, Independent Director | ||
| Anna Protopapas, President CEO, Director | ||
| Timothy Lowinger, Chief Scientific Officer | ||
| Donald Bergstrom, Chief Medical Officer | ||
| Kristen Hege, Independent Director | ||
| Alejandra JD, Secretary SVP | ||
| David Mott, Chairman of the Board | ||
| Mikhail Papisov, CoFounder |
Mersana Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mersana Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.66 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (1.96) % | ||||
| Current Valuation | 208.06 M | ||||
| Shares Outstanding | 121.3 M | ||||
| Shares Owned By Insiders | 1.31 % | ||||
| Shares Owned By Institutions | 94.47 % | ||||
| Number Of Shares Shorted | 10.58 M | ||||
| Price To Earning | (0.98) X | ||||
| Price To Book | 12.49 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Mersana Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Mersana Therapeutics' short interest history, or implied volatility extrapolated from Mersana Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Mersana Stock analysis
When running Mersana Therapeutics' price analysis, check to measure Mersana Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mersana Therapeutics is operating at the current time. Most of Mersana Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mersana Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mersana Therapeutics' price. Additionally, you may evaluate how the addition of Mersana Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Mersana Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 0.317 | Quarterly Revenue Growth (0.27) | Return On Assets (0.38) | Return On Equity (2.66) |
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.